This bill creates a legal protection that allows generic drug and biosimilar manufacturers to develop and seek approval for new versions of existing drugs without being sued for patent infringement, as long as they follow specific labeling rules. Here's what that means in practice: when a pharmaceutical company wants to bring a cheaper generic or biosimilar version of a drug to market, they currently have to worry about being sued by the original drug maker for infringing on patents related to how the drug is used. This bill says that simply applying for approval, marketing the drug with FDA-approved labeling, or describing it as generic or biosimilar won't count as patent infringement—but only if the company doesn't advertise or label the drug for the specific medical conditions that the original patent covers.

The practical effect is that generic and biosimilar manufacturers get more freedom to bring affordable alternatives to patients faster, without getting tangled up in patent lawsuits over how the drug is used. For example, if a company develops a generic version of a pain medication, they can seek FDA approval and sell it without fear of being sued, as long as their label and marketing don't claim it treats the specific conditions covered by the original patent. This protects patients' access to cheaper medications while still respecting the original drug maker's patent rights for the specific uses they invented. The bill applies to both traditional drugs and biological products like insulin or monoclonal antibodies, and it covers any lawsuits that were already pending when the law takes effect.

Skinny Labels, Big Savings Act

Cline, Ben

Skinny Labels, Big Savings ActThis bill provides a statutory safe harbor from patent infringement claims for generic or&nbsp;biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.Under current law, the Food and Drug Administration (FDA) may approve generic and&nbsp;biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics.The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act:<ul><li>submitting or seeking approval of a skinny label for a generic or biosimilar drug;</li><li>promoting or commercially marketing a drug with skinny labeling approved by the FDA; or</li><li>describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug.</li></ul>The bill also applies the safe harbor to similar actions under the Public Health Service Act.